Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt to Build R&D Data Utilization Platform at AMED
June 3, 2021
- Nonpartisan Lawmakers’ Group Launched for Dementia Measures
June 2, 2021
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Japan to Roll Out COVID-19 Vaccines at Workplaces from June 21
June 2, 2021
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- Eisai’s EZH2 Inhibitor, 3 More New Drugs Clear Key Panel, June OK Likely
May 31, 2021
- Panel OK’s Pfizer Vaccine Use in Age 12-Plus, Longer Refrigerator Storage
May 31, 2021
- Olumiant Added to MHLW’s COVID-19 Guide as Approved Drug
May 28, 2021
- LDP Lawmakers Urge Expanded Fertility Treatment Support via Coverage, Subsidies
May 28, 2021
- Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Next Drug Distribution Confab Set for July 2 after Bid-Rigging Verdicts
May 27, 2021
- Trintellix Braced for Price Cut as Chuikyo OKs CEA Results, Coralan Intact
May 27, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
- LDP Economic Growth HQ Hammers Out Proposal for Honebuto Paper
May 26, 2021
- Moderna Vaccine Likely to Be Used for Workplace Vaccination
May 26, 2021
- Japan Eyes Pfizer Vaccine Use in Younger People, Longer Refrigerator Storage
May 26, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…